Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06801591 in Advanced Malignancies and NSCLC
NCT04181788Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of sasanlimab in advanced cancer and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities at 42 days, Area Under the Curve at Steady State at Cycle 3 and 1 more. Started Mar 2020; status: completed.
02
Drugs
sasanlimab
03
Conditions
advanced cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04181788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04181788.